Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has issued an update.
Infant Bacterial Therapeutics AB reported no net sales and a reduced operating loss for the third quarter of 2025, reflecting ongoing investment in their lead product, IBP-9414. The company achieved a significant milestone with the FDA granting Breakthrough Therapy Designation for IBP-9414, which showed a 27% reduction in mortality in a Phase 3 study. Efforts are underway to secure market approval in the US and Europe, with plans to submit a Biological License Application in 2026, positioning the company for potential market entry and partnerships for global distribution.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB operates in the biotechnology industry, focusing on developing treatments for severe medical conditions in infants. Their primary product, IBP-9414, is aimed at reducing gastrointestinal-related mortality in newborns, with a significant focus on securing market approval in the US and Europe.
Average Trading Volume: 12,672
Technical Sentiment Signal: Hold
Current Market Cap: SEK832.5M
Find detailed analytics on IBT.B stock on TipRanks’ Stock Analysis page.